← Back to Search

Positron Emission Tomography/Computed Tomography for Prostate Cancer

Phase 2
Waitlist Available
Led By Orhan K Oz, MD, PhD
Research Sponsored by Dana Mathews
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients being considered for salvage therapy.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights

Study Summary

This trial will test if a new imaging method can better detect prostate cancer recurrence than current methods, and if so, if it can help guide treatment decisions.

Eligible Conditions
  • Prostate Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are being considered for a treatment that is used when other treatments have not worked.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Location of recurrence
Residual prostate cancer

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients with suspected BCR or metastatic prostate cancerExperimental Treatment2 Interventions
Patients with suspected BCR or metastatic prostate cancer
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Positron Emission Tomography/Computed Tomography
2020
Completed Phase 2
~20
68Ga PSMA-11 injection
2020
Completed Phase 2
~20

Find a Location

Who is running the clinical trial?

Dana MathewsLead Sponsor
2 Previous Clinical Trials
20 Total Patients Enrolled
2 Trials studying Prostate Cancer
20 Patients Enrolled for Prostate Cancer
Orhan K Oz, MD, PhDPrincipal InvestigatorUT Southwestern Medical Center
2 Previous Clinical Trials
20 Total Patients Enrolled
2 Trials studying Prostate Cancer
20 Patients Enrolled for Prostate Cancer
Neil Rofsky, MD, MHAPrincipal InvestigatorUT Southwestern Medical Center
2 Previous Clinical Trials
20 Total Patients Enrolled
2 Trials studying Prostate Cancer
20 Patients Enrolled for Prostate Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current enrolment rate for this research study?

"Affirmative. Data from clinicaltrials.gov demonstrates that this trial, which was initially advertised on March 19th 2021, is currently searching for participants. The team needs to recruit 50 people from a single medical centre."

Answered by AI

Are there any vacancies available for participants in this clinical research study?

"According to clinicaltrials.gov, the study is currently enlisting participants. The trial was first published on March 19th 2021 and the most recent update occurred on February 3rd 2022."

Answered by AI

Is the FDA compliant with Positron Emission Tomography/Computed Tomography?

"Positron Emission Tomography/Computed Tomography received a safety score of 2 on the scale from 1 to 3. This is because it has completed Phase 2 trials, wherein some proof of its security was established yet there remains no evidence for its efficacy."

Answered by AI
~0 spots leftby Mar 2025